Journal article

Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor

Bruce G Livett, David W Sandall, David Keays, John Down, Ken R Gayler, Narmatha Satkunanathan, Zeinab Khalil



Pain therapeutics discovered by molecular mining of the expressed genome of Australian predatory cone snails are providing lead compounds for the treatment of neurological diseases such as multiple sclerosis, shingles, diabetic neuropathy and other painful neurological conditions. The high specificity exhibited by these novel compounds for neuronal receptors and ion channels in the brain and nervous system indicates the high degree of selectivity that this class of neuropeptides can be expected to show when used therapeutically in humans. A lead compound, ACV1 (conotoxin Vc1.1 from Conus victoriae), has entered Phase II clinical trials and is being developed for the treatment for neuropathic..

View full abstract

University of Melbourne Researchers